Dr. Arlene Chapman is a distinguished nephrologist and Professor of Medicine at the University of Chicago, where she also serves as the Chief of the Section of Nephrology. She is a member of the American Association of Physicians and the American Clinical and Climactologic Association. Her clinical efforts and research focuses on hereditary kidney diseases, particularly autosomal dominant polycystic kidney disease (ADPKD), essential hypertension, and the intersection of kidney function and pregnancy.
Over the past three decades, Dr. Chapman has been a leading figure in ADPKD research, contributing to the development of magnetic resonance imaging techniques to assess total kidney volume (TKV), a key biomarker in disease progression. Her work has been instrumental in advancing clinical trials for novel therapies, including vasopressin V2 receptor antagonists and rigorous blood pressure control strategies.
In recognition of her significant contributions, Dr. Chapman received the 2020 Lillian Jean Kaplan International Prize from the International Society of Nephrology. This award honors her pioneering efforts in ADPKD research, the development of Vasopressin V2 receptor antagonists. the development of TKV as a prognostic imaging biomarker and her leadership in interventional clinical trials that have led to FDA-approved treatments for ADPKD.
Beyond her research, Dr. Chapman is a dedicated educator and mentor, actively involved in training medical students, residents, fellows and faculty. She has published over 200 peer-reviewed articles and 20 book chapters and has served on the editorial boards of several prominent nephrology journals.
Dr. Chapman is an Associate Director of the Institute for Translational Medicine and Director of the Clinical Research Center at the University of Chicago and has recently established a whole room calorimetry core for investigators interested in energy expenditure and metabolism. Dr. Chapman continues to lead innovative research initiatives across different medical disorders and plays a key role in clinical research leadership at the University of Chicago.
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2025 Apr 01; 20(4):520-528.
PMID: 39970002
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025 Feb; 107(2):234-254.
PMID: 39848746
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease.
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2025 Apr 01; 20(4):563-572.
PMID: 39874088
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence Program.
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence Program. Kidney360. 2025 Jan 01; 6(1):159-166.
PMID: 39560608
Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKD.
Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKD. Kidney Int Rep. 2025 Feb; 10(2):447-456.
PMID: 39990913
Building a Physician/Advanced Practice Provider Partnership for Inpatient Dialysis Care.
Building a Physician/Advanced Practice Provider Partnership for Inpatient Dialysis Care. Kidney360. 2024 Dec 01; 5(12):1922-1924.
PMID: 39466362
Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension.
Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension. J Am Soc Nephrol. 2025 Jan 01; 36(1):34-47.
PMID: 39302726
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials.
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials. Am J Kidney Dis. 2025 Jan; 85(1):127-130.
PMID: 39154887
In memoriam: George L. Bakris, MD, 1952-2024.
In memoriam: George L. Bakris, MD, 1952-2024. Kidney Int. 2024 Aug 14.
PMID: 39178909
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers.
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers. Clin Transl Sci. 2024 May; 17(5):e13816.
PMID: 38747311